Home About us Current issue Ahead of Print Back issues Submission Instructions Advertise Contact Login   

Search Article 
Advanced search 
Saudi Journal of Kidney Diseases and Transplantation
Users online: 1396 Home Bookmark this page Print this page Email this page Small font sizeDefault font size Increase font size 

EDITORIAL Table of Contents   
Year : 2007  |  Volume : 18  |  Issue : 3  |  Page : 333-336
Interferon-Beta for Glomerulonephritis?

London NW1 8JS, United Kingdom

Correspondence Address:
E Nigel Wardle
London NW1 8JS
United Kingdom
Login to access the Email id

Source of Support: None, Conflict of Interest: None

PMID: 17679741

Rights and PermissionsRights and Permissions

Interferon beta (IFNβ) is used in the therapy of multiple sclerosis (MS), which develops from the activation of autoreactive T lymphocytes against peptides of myelin basic protein. IFNβ was demonstrated to have beneficial effects in experimental models of glomerulonephritis (GN), such as decreasing proteinuria via Il-10 release. T helper (Th-1) lymphocyte responses are reduced, the actions of metalloproteinase (MMP9) are suppressed, and the functions of regulatory T cells are promoted. In concept, IFNI3 therapy might be beneficial in patients with life threatening forms of GN, such as Goodpasture's syndrome or vasculitis. Further research is warranted to study the effect of IFNβ on GN in clinical settings.

Print this article  Email this article

  Similar in PUBMED
    Search Pubmed for
    Search in Google Scholar for
   Citation Manager
  Access Statistics
   Reader Comments
   Email Alert *
   Add to My List *
 * Requires registration (Free)

 Article Access Statistics
    PDF Downloaded351    
    Comments [Add]    

Recommend this journal